CHREDICINE


Development of a human PCSK9targeting epigenetic editor with durable, near-complete in vivo silencing

Aron Jaffe, SVP, Head of Research




© 2023 Chroma Medicine, Inc.

### Epigenetics regulates gene expression to determine cell identity and function



#### Chromatin packaging and epigenetics regulates DNA transcription





Epigenetic editing leverages the cell's endogenous system to precisely control gene expression


Durable change in phenotype without a change in genotype

#### **Epigenetic Repressor** *Methylates Targets*

# Nucleosome


**Gene is Active** DNA is Open and Accessible **Epigenetic Activator** *Demethylates Targets* 

#### **Gene is Inactive** DNA is Closed and Inaccessible






### Chroma's epigenetic editors are single fusion proteins with three functional domains



- DNA binding domain precisely localizes effector domains to target sequence
- Transcription effector domain transiently represses target gene
- Methylation effector domain durably silences target gene



# CpG methylation spanning the TSS governs PCSK9 expression across cell types




- WGBS analysis of 205 methylomes from 39 different cell types from 137 donors
- Patterns are very consistent across individuals within a cell type (>99.5% identical), and across cell types (>95% identical)
- Focal patterns around promoters and enhancers are the sites of differences across cell types and determine gene expression
- PCSK9 methylation spanning the TSS is inversely correlated with expression




Loyfer et al., Nature 2023

### Epigenetic editor screen identified multiple potent PCSK9 gRNAs

PCSK9 gRNA Screen




#### **Hit Confirmation: Dose Response**





# Epigenetic silencing of PCSK9 is highly specific with no off-target changes in expression or methylation

- Lead gRNAs demonstrated high specificity with epigenetic repressor in primary human hepatocytes *in vitro*
  - No off-target changes in expression (RNA-seq)
  - No off-target methylation (Illumina Methylation Array, not shown)



#### **Epigenetic Repressor Specificity Analysis: Expression of Targeted vs. Control**

CHR C A

## Chroma's epigenetic editors are highly efficacious and durable in vivo

+

KRAB

**Epigenetic Editor** 

- Transgenic mouse containing human PCSK9 locus
- Controls:
  - Cas9 nuclease: durable, 90% reduction of PCSK9
  - CRISPRi: transient reduction of PCSK9

mRNA + gRNA


CRISPR

OR

 Epigenetic editor achieves 99% silencing, durable at least 5 months post-dose

KRAB

OR




Single administration

Periodic bleeds; PCSK9 analysis by ELISA





### Chroma's epigenetic editor induces stable, targeted CpG methylation at the human PCSK9 TSS in vivo



MEDICINE

Methylation of PCSK9 locus at Day 28

### Chroma's epigenetic editors are easily reprogrammable Robust and durable reduction of HBV markers in Tg-HBV mouse model

- Editor retargeted to HBV by changing gRNA sequence
- Transgenic mouse containing the HBV virus
- Effective and durable reduction of HBsAg (below LLOQ)
- Similar reduction seen in circulating viral HBV DNA


╋

KRAB

**Epigenetic Editor** 

mRNA + gRNA

OR



Tg-HBV mouse
Single administration
Periodic bleeds; HBV biomarkers analyzed by ELISA




10

### Summary

- Epigenetic editing leverages an endogenous mechanism for regulating gene expression
- Chroma's epigenetic editors robustly and durably silence multiple targets in vivo
  - Prototype epigenetic editor drove robust silencing of mPCSK9, durable through partial hepatectomy (Cappellutti et al., ASGCT 2023)
  - Chroma's PCSK9 epigenetic editor highly specific
  - PCSK9 epigenetic editor achieved durable, 99% silencing in vivo
  - HBV-targeted epigenetic editor achieved durable silencing of HBsAg in vivo below the LLOQ

#### Chroma epigenetic editor robustly and durably silences multiple targets in vivo





### Acknowledgements

#### Thank you to the entire Chroma team and our partners!







# CHREDICINE

© 2023 Chroma Medicine, Inc.